Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (2845)	3/18/2013 12:36:47 PM
From: former_pgs	Respond to of 3202

>Assuming rux has no effect at all on PML, how long will it be before this can be demonstrated with a reasonable degree of statistical confidence ?< Dunno. I think that is tough to answer. The other question for me is how the disease contributes to this. INCY referred to the patients they've treated to date, but in a sense we have a much larger safety catalog for JAK1/2 inhibition through the Pfizer drug. I'm trying to get a handle on how useful those data are for understanding what the risk is here.